• Ceapin-A7 and the Next Phase of ER Stress Research

  2026-08-24

  Ceapin-A7 provides a selective way to interrogate ATF6α signaling alongside the PERK–JAK1–STAT3 axis implicated in nucleus pulposus cell pyroptosis. This thought-leadership analysis connects pathway-selective pharmacology with translational study design for intervertebral disc degeneration and broader endoplasmic reticulum stress research.

• AP20187 Workflows for Controlled Dimerization

  2026-08-23

  AP20187 gives researchers temporal control over engineered signaling proteins, enabling conditional gene expression, regulated cell therapy, and metabolic assays. This guide connects practical dimerizer workflows with a chronic intermittent hypoxia pain model while clearly separating validated findings from assay-development opportunities.

• HyperScript™ Reverse Transcriptase for RNA Workflows

  2026-08-22

  Learn how HyperScript™ Reverse Transcriptase supports cDNA synthesis for qPCR when RNA is scarce, structured, or difficult to copy. This workflow-focused guide connects the enzyme’s thermal stability and reduced RNase H activity to transcriptomic validation in RPE/choroid and other demanding assays.

• FAST Food-Grade Nutraceutical Nanoparticles: Study Analysis

  2026-08-22

  This study evaluates Facilitated Self-Assembling Technology as a surfactant-free, food-grade route for producing stable nanoparticles from poorly soluble nutraceuticals. Its strongest evidence concerns particle formation, colloidal stability, simulated gastric behavior, and in-vitro compatibility, while direct enhancement of oral bioavailability remains to be demonstrated.

• Belinostat (PXD101): HDAC Research Guide

  2026-08-21

  Belinostat, also called PXD101, is a hydroxamate-type pan-HDAC inhibitor for preclinical epigenetic cancer research. Product data report nanomolar HDAC activity, histone H3/H4 acetylation, tumor-cell growth inhibition, and a bladder-tumor benchmark in mice, while these findings do not establish clinical efficacy.

• Tropifexor: An Assay-First FXR Research Guide

  2026-08-20

  Tropifexor (LJN452) is a potent FXR agonist for connecting receptor activation with intestinal barrier and metabolic phenotypes. This assay-first guide explains how the neonatal piglet and patient-derived organoid study can inform model selection, endpoints, controls, and interpretation.

• AZD8055 Protocol Guide for mTOR Pathway Studies

  2026-08-20

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1/mTORC2 signaling, cancer cell proliferation, and selected metabolic endpoints. It is appropriate for preclinical mechanistic work but should not be selected when water solubility, validated clinical efficacy, or a defined clinical dosing regimen is essential.

• Quercetin Protects Cataract Lenses via Hippo Signaling

  2026-08-19

  This 2025 study combines network pharmacology, a UVB-induced cataract mouse model, and oxidatively injured lens epithelial cells to investigate how quercetin protects the lens. Its central contribution is the use of α-hederin-mediated pathway reactivation to connect Hippo signaling changes with oxidative stress, epithelial proliferation, and cataract-related tissue damage.

• From RNA Cargo to Translational Readout

  2026-08-19

  A translational framework for using dual-fluorescence mRNA to separate delivery, intracellular trafficking, and protein expression—and to connect those measurements with emerging RNA nanoparticle design rules.

• Midecamycin: Designing Better Antibacterial Assays

  2026-08-18

  Midecamycin is an acetoxy-substituted macrolide antibiotic for targeted bacterial protein synthesis studies. This guide connects ribosome-level pharmacology with perfusion-aware assay design to improve interpretation of antibacterial data.

• Sulfachloropyridazine: From DHPS to Microbiome Strategy

  2026-08-18

  Sulfachloropyridazine offers translational researchers a practical bridge from DHPS biochemistry to antimicrobial phenotyping and microbiome-aware infection models. This article examines how to validate target engagement, interpret cecal microbiome findings, and design research workflows that distinguish direct antibacterial effects from broader ecological and metabolic responses.

• Tigecycline A5226: Reliable Assay Workflows

  2026-08-17

  This scenario-based guide explains how Tigecycline (SKU A5226) can be incorporated into cell viability, proliferation, cytotoxicity, and infection-model workflows without confusing antimicrobial effects with host-cell injury. It connects documented formulation data with current carbapenem-resistant Enterobacter cloacae epidemiology to support practical, reproducible experimental decisions.

• n-Dodecyl-β-D-maltoside for WecA Assays

  2026-08-17

  Discover how n-Dodecyl-β-D-maltoside and DDM can be optimized as assay variables rather than treated as passive extraction reagents. This guide connects micelle chemistry, WecA purification, kinetic readouts, surface adsorption, and protein–lipid interaction studies.

• PS Nanoplastics Rewire Vascular Lipid Signaling

  2026-08-16

  A 2026 study links prenatal and lactational exposure to polystyrene nanoplastics with lipid accumulation in vascular smooth muscle cells of male offspring through the MAPK/ERK/UHRF1 axis. Pharmacological ERK-pathway inhibition and UHRF1 knockdown provide complementary evidence that this signaling cascade contributes to early vascular lipid dysregulation.

• Tigecycline in the Resistance-Transfer Era

  2026-08-15

  Tigecycline offers translational researchers a mechanistically distinct glycylcycline antibiotic for studying resistant bacterial phenotypes. By connecting 30S ribosomal inhibition with the plasmid-mediated transmission dynamics reported in carbapenem-resistant Enterobacter cloacae, this article outlines a practical framework for in vitro, in vivo, and clinical research decisions.

8637 records 1/576 page Next 12345 下5页 Last page